MarginsXMarginsX
Home › Markets › Health Care › BDTX

Black Diamond Therapeutics Inc. (BDTX)

BDTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.53
+4.08% on the day
Market cap
$87.9M
Micro cap
Revenue · 2025
$70.0M
Prior year not contiguous
Net income · 2025
$22.4M
32.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1701541/000170154126000009/0001701541-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBDTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001701541
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$70.0M
Net income$22.4M
Operating income$12.5M
Net margin32.0%
Operating margin17.9%
Revenue growthNo prior-year revenue to compare
Cash$21.0M
Total assets$143.0M
P/E (computed)3.9×
P/S (computed)1.3×

Warning signs

Cash runway
5.4 months
$15.1M cash at September 30, 2026
Share count, 1 year
+0.9%
2025-10-30 to 2026-11-05 · +11.3% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$15.1M cash; operating cash flow -$8.3M a quarter.Report 2026-09-30
Shares outstanding57,468,255 (2026-11-05); 56,974,913 a year earlier; 51,635,184 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$10.0M-$8.3M$15.1MNo debt tags$010-Q 2026-11-10
Q2 2026
2026-06-30
$0-$9.9M-$8.0M$19.2MNo debt tags$010-Q 2026-08-05
Q1 2026
2026-03-31
$0-$9.0M-$10.2M$30.1MNo debt tags$010-Q 2026-05-07
Q4 2025
2025-12-31
$0-$15.1M-$6.8M$21.0MNo debt tags$70.0M10-K 2026-03-16
Q3 2025
2025-09-30
$0-$8.5M-$7.8M$30.9MNo debt tags$70.0M10-Q 2026-11-10
Q2 2025
2025-06-30
$0-$10.6M-$9.2M$30.0MNo debt tags$70.0M10-Q 2026-08-05
Q1 2025
2025-03-31
$70.0M$56.5M$53.4M$98.4MNo debt tags$70.0M10-Q 2026-05-07
Q4 2024
2024-12-31
$0-$16.0M-$15.1M$36.4MNo debt tags$010-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-11-13
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 487 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.3%
1 month-12.5%
3 months-27.2%
Year to date-39.5%
1 year-67.3%
From 52-week high-63.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
OTLKOutlook Therapeutics Inc.$0.3960-4.12%$96.4M
CHRSCoherus Oncology Inc.$0.5059-3.73%$78.2M
MOLNMolecular Partners AG$2.70-8.21%$101.2M
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
TNYATenaya Therapeutics Inc.$0.3336-4.47%$76.0M
AVXLAnavex Life Sciences Corp.$0.8176-12.42%$75.8M
ZURAZura Bio Limited$1.08-12.90%$104.0M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier